



A pilot study of engineered adenovirus ONCOS-102 in combination with pembrolizumab in checkpoint inhibitor refractory advanced or unresectable melanoma

Contributing authors:

Alexander Shoushtari
Anthony J. Olszanski
Thomas J. Hornyak
Jedd Wolchok
Sylvia Vetrhus
Karianne Risberg Handeland
Lukasz Kuryk
Magnus Jäderberg

Memorial Sloan Kettering Cancer Center
Fox Chase Cancer Center
University of Maryland Greenebaum Cancer Center
Memorial Sloan Kettering Cancer Center
Targovax ASA
Targovax ASA
Targovax Oy
Targovax ASA

Dr. Alexander Shoushtari
Memorial Sloan Kettering Cancer Center



Society for Immunotherapy of Cancer

#SITC2019

Disclosures

Advisory boards

- Bristol Myers Squibb
- Immunocore
- Castle Biosciences

Clinical Trial Support

- Targovax
- Bristol Myers Squibb
- Immunocore
- Xcovery
- AstraZeneca

Outline



Background and Study Design



Safety of ONCOS-102 + pembrolizumab




Clinical Responses in Part 1





Systemic and Local Immune Responses in Part 1

Limited treatment options for anti PD-1 refractory melanoma



ONCOS-102 is an oncolytic adenovirus serotype 5 armed with a GM-CSF transgene




Study Design

Part 1

3x ONCOS-102

8x pembrolizumab

enrollment completed




Part 2

3x ONCOS-102

8x ONCOS-102 +

pembrolizumab

enrolling



Imaging

CPO: Cyclophosphamide


Study Design

Part 1

3x ONCOS-102

8x pembrolizumab

enrollment completed




Part 2

3x ONCOS-102

8x ONCOS-102 +

pembrolizumab

enrolling



Imaging

CPO: Cyclophosphamide

Demographics and prior treatment

Parameters	Number of patients (n=9)
Age (Y) median (range)	73 (40 – 87)
Gender, n	
Female	4
Male	5
Histological type	
Cutaneous	8
Acral	1
Stage at enrollment	
III	1
IIIB	2
IIIC	3
IV	2
IVM1c	1

Prior therapy	Number of patients (n=9)
Systemic Therapy	
anti-PD1 checkpoint inhibitor Pembrolizumab and/or Nivolumab	9
anti-CTLA4 checkpoint inhibitor Ipilimumab	4
Oncolytic virus Talimogene-laherparepvec	3
BRAF/MEK inhibitors Dabrafenib + Trametinib	2
TLR9 agonist CMP-001 (investigational)	1
Interleukin-2 immunotherapy	1
Surgery	7
Radiotherapy	1
Chemotherapy	1

Preliminary data

Adverse Events *

Adverse Event Preferred term	No. of events	No. of patients	CTCAE grade	Relationship to study drug
Chills	7	5	1, 2	ONCOS-102
Myalgia	6	3	1	
Pyrexia	5	3	1, 2	
Diarrhoea	4	3	1	
Nausea	3	3	1	
Alanine aminotransferase increased	2	2	1	
Fatigue	2	2	1, 2	
Vomiting	2	2	1	
Rash maculo-papular	2	2	1	
Injection site pain	2	1	1	
Injection site swelling	1	1	2	
Peripheral oedema	1	1	2	
Infectious colitis	1	1	3 **	
Productive cough	1	1	2	Pembrolizumab
Haemolytic anemia	1	1	3 **	
Diarrhoea	2	2	1,3 **	
Diabetic ketoacidosis	1	1	4 **	ONCOS-102 and pembrolizumab
Type 1 diabetes mellitus	1	1	4 **	

* AEs occurring in 2 or more
Patients or grade 2 or higher


** SAEs

Total no. of AEs reported:
58 in 9 patients

Preliminary data


Objective Response Rate of 33% (3 of 9 pts)

RECIST 1.1



Preliminary data

Targeted lesions: best % change in tumor burden from baseline



Preliminary data

Example of response: Patient with CR

Tumor stage at enrollment: **IIIb**
T4a, N2b, M0

Prior therapies: Surgery
Ipilimumab
Dabrafenib + Trametinib
Pembrolizumab



RECIST 1.1: CR



Preliminary data

Upregulation of proinflammatory cytokines in all patients



Systemic expression of proinflammatory cytokines





Preliminary data

Systemic increase in tumor targeting T-Cells

IFN γ ELISPOT, spot number/25,000 cells




* Week 3 analysis not performed



Preliminary data

Increased T-cell infiltration in ONCOS-102 injected tumors is necessary but not sufficient for response

CD8+ T-cell tumor infiltration, -fold change from baseline



Conclusions

Sequential ONCOS-102 and pembrolizumab treatment in advanced anti-PD1 refractory melanoma patients showed:

- Acceptable safety profile; most common ONCOS-102 related adverse events were fevers, chills, and myalgias
- ORR: 3 of 9 patients (RECIST 1.1)
- Upregulation of proinflammatory cytokines
- Increased infiltration of CD8+ T cells in ONCOS-102 injected tumors
- Systemic development of anti-tumor immune responses

Part 2 of this pilot study is currently enrolling an additional 12 patients to receive 12 injections of ONCOS-102 with pembrolizumab

Acknowledgements

Patients and their family members



Memorial Sloan Kettering Cancer Center

Philip Wong
Taha Merghoub
Nana Prempeh Keteku
Brooke Freeman
Mimma Errante
Paul Chapman
Michael Postow
Margaret Callahan
Parisa Momtaz
Charlotte Ariyan
Allison Betof Warner
Shalom Sabwa
Olivia Gibson



Fox Chase Cancer Center

Linda Thibodeau



University of Maryland Greenebaum Cancer Center

Petr Hausner
Cheryl Young
Research study team



Targovax

Anne-Sophie Møller
Trine Jensen Gjertsen